Drug Trial Radar · NCT01416194
Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,497
Actual
Start
Jul 25, 2011
Primary completion
Apr 30, 2019
Study completion Apr 30, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 12, 2011
Design
- Study type
- Observational
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.
Conditions
- Osteoporosis, Postmenopausal
Interventions
BazedoxifeneDrug
Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
BisphosphonateDrug
Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
RaloxifeneDrug
Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Incidence of Venous Thromboembolism (VTE)Time frame: Up to a maximum of follow-up period of 92.1 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.